News

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, leading to prolonged survival.

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.

The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.

COCOON skin care led to fewer or milder dermatologic symptoms with amivantamab/lazertinib vs standard care in patients with EGFR+ advanced NSCLC.

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to Jonathan Goldman, MD.

Treatment with imlunestrant was especially impactful to quality of life and global health status for patients with ESR1 mutations.

The combination of niraparib with abiraterone acetate and prednisone (AAP) boosted rPFS vs AAP plus placebo in HRR-mutated mCSPC.

Seventy-three percent of patients with breast and other solid tumors did not experience ILD recurrence when rechallenged with trastuzumab.

Adding durvalumab to perioperative FLOT upped event-free survival in patients with gastric or gastroesophageal adenocarcinoma eligible for resection.

Camizestrant plus CDK4/6 inhibition improved PFS vs standard care in patients with ER+/HER2– advanced breast cancer and emergent ESR1 mutations.

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with cisplatin/radiotherapy in LA-SCCHN.

Atezolizumab plus chemotherapy reduced risk of death or recurrence by 50% compared with chemotherapy alone for patients with stage III dMMR colon cancer.

Patients with stage III resected colon cancer had lower risk of death with less inflammatory diets and more regular physical activity.

Sacituzumab govitecan/pembrolizumab in the first line lengthened PFS vs chemotherapy/pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

T-DXd led to improvements in OS, PFS, ORR, and DOR compared with ramucirumab/paclitaxel in the second line for HER2-positive gastric and GEJ cancer.

Patients with ESR1-mutated, ER-positive, HER2-negative, advanced breast cancer experienced an increase in PFS with vepdegestrant compared with fulvestrant.

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

Encorafenib and cetuximab plus mFOLFOX6 increased progression-free survival for patients with metastatic colorectal cancer harboring BRAF V600E mutations.

The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell lung cancer.

Adding immunotherapy to chemo may boost pCR and downstaging rates in the neoadjuvant setting for muscle-invasive bladder cancer.

SVR10 at week 12 with pacritinib was linked to longer overall survival in patients with myelofibrosis and thrombocytopenia.

An oncology nurse shares advice for avoiding exhaustion and soreness when administering subcutaneous injections.

The VENTANA MET (SP44) RxDx Assay is now FDA approved to identify patients with NSCLC eligible for telisotuzumab vedotin.

Patients with HR-positive, HER2-negative metastatic breast cancer should be consistently tested for ESR1 mutations to inform next lines of therapy.

CRS and ICANS rates were similar in adults 75 years or older vs younger individuals with relapsed/refractory multiple myeloma.

Patients with mantle cell lymphoma and large clonal hematopoiesis clones had shorter progression-free and overall survival compared with those without clones.

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC lacking HRR mutations.